SurModics (SRDX) Tops Q1 EPS by 7c

SurModics (NASDAQ: SRDX) reported Q1 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $22.3 million versus the consensus estimate of $22.37 million.

“The entire Surmodics team is wholeheartedly pleased with the results of our TRANSCEND clinical trial, which demonstrates comparable safety and effectiveness of our SurVeil drug-coated balloon using a substantially lower drug dose than the comparative product,” said Gary Maharaj, President and CEO of Surmodics, Inc. “Our proprietary coating technology is the key to SurVeil, which was designed to optimize drug delivery, transfer, retention and durability. We are one step closer to our goal of providing physicians with an attractive therapeutic alternative to improve the treatment of peripheral arterial disease.”

For earnings history and earnings-related data on SurModics (SRDX) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance